Clinical Trial Update: An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the combination of bortezomib and sorafenib in advanced malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Nexavar (Sorafenib)
• Velcade (bortezomib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Melanoma | Phase 1 | Status: COMPLETED